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INTRODUCTION 
 
Gastric cancer (GC), also known as stomach cancer, 
develops from the cells lining of the stomach. In 2018, 
more than one million new cases of gastric cancer were 
diagnosed, and an estimated 783,000 associated deaths 
occurred. One out of 12 cancer deaths worldwide 
resulted from GC, making it the fifth most common 
cancer and the third leading cause of death due to 
cancer [1]. Gastric cancer poses a particularly serious 
health problem in Eastern Asia. Parkinson’s disease is a 
long-term degenerative disorder of the central nervous 
system that mainly affects the motor system. It is 
currently listed as the second most prevalent 
neurodegenerative disorder after Alzheimer’s disease 
and the most common disorder affecting body 
movements [2]. The causes of Parkinson’s disease and 
gastric cancer are very complicated, and increasing 
evidence supports the involvement of both genetic and 
environmental factors. 
 
It is believed that the gastrointestinal tract comprises an 
intrinsic nervous system — the enteric nervous system 
(ENS). Referred to as “the second brain” [3], the ENS 
regulates the gastrointestinal tract’s motility and owns 
neuroendocrine functions. The ENS interacts bi-
directionally with the Central Nervous Systems (CNS), 
in a connection referred to as the “brain-gut axis” [4], 
which is composed of neural pathways in the CNS, 
autonomic nervous system, and the hypothalamic-
pituitary-adrenal axis. A large number of patients with 
Parkinson’s disease experience constipation, abdominal 
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Gastric cancer is a disease that develops from the lining of the stomach, whereas Parkinson’s disease is a long-
term degenerative disorder of the central nervous system that mainly affects the motor system. Although these 
two diseases seem to be distinct from each other, increasing evidence suggests that they might be linked. To 
explore the linkage between these two diseases, differentially expressed genes between the diseased people 
and their normal controls were identified using the barcode algorithm. This algorithm transforms actual gene 
expression values into barcode values comprised of 1’s (expressed genes) and 0’s (silenced genes). Once the 
overlapped differentially expressed genes were identified, their biological relevance was investigated. Thus, 
using the gene expression profiles and bioinformatics methods, we demonstrate that Parkinson’s disease and 
gastric cancer are indeed linked. This research may serve as a pilot study, and it will stimulate more research to 
investigate the relationship between gastric cancer and Parkinson’s disease from the perspective of gene 
profiles and their functions. 
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distension, and other gastrointestinal symptoms before 
they experience motor symptoms [5]. More importantly, 
dysbiosis of gut microbiota plays a critical role in the 
pathogenesis of Parkinson’s disease, such as [6]. On the 
other hand, gastrointestinal symptoms and microbiome 
dysbiosis frequently occur in patients with gastric 
cancer [7]. Especially, increased gut permeability 
promotes the leakage of bacteria and their products into 
the blood, leading to the maturation of antigen-
presenting cells and thus the stimulation of 
inflammatory pathways that are of crucial importance in 
these two diseases. 
 
Epidemiological studies [8–12] have suggested that 
patients with Parkinson’s disease have a reduced risk of 
developing cancers, including gastric cancer, compared 
to people who do not have Parkinson’s disease. 
Nevertheless, other studies have showed a positive 
association between Parkinson’s disease and cancers, 
that is, an increased risk of cancers in patient with 
Parkinson’s disease [13, 14]. For instance, for gastric 
cancer, the hazard ratio was 1.59 (95% CIs: 1.30-1.94) 
by Lin et al. [14], who attributed the inconsistency to 
the fact that most of those epidemiological studies were 
carried out upon the Western population, while their 
study was performed in Taiwan. Therefore, Lin et al. 
[14] concluded that the race or/and environmental 
exposures have an interactive effect on the association 
between cancers and Parkinson’s disease. Also, the 
Columbia Open Health Data (COHD) [15], which is 
based on electronic health records (EHR), indicated that 
the concurrence of Parkinson’s disease and gastric 
cancer is significantly higher than what expected by 
chance (odds ratio=2.02, p=2.23×10-6). This implies 
that both diseases are positively related. It is worth 
noting that patients in the electronic health records may 
not represent the general population; thus, the 
association between the two diseases may be biased. 
Therefore, it is natural to speculate that Parkinson’s 
disease and gastric cancer may be linked. 
 
At the molecular level, studies suggest that 
neurodegenerative disorders (including Alzheimer’s 
disease, Parkinson’s disease, and Huntington’s disease) 
and cancers (including lung cancer, liver cancer, and breast 
cancer) are linked to each other with respect to somatic 
mutations, mRNAs or microRNAs, such as [16–19]. 
However, only a few of the studies focused on the specific 
association between Parkinson’s disease and gastric cancer 
from this perspective [20, 21]. For example, Hu and 
colleagues [20] demonstrated that a specific miRNA, miR-
148a, is not only a potential tumor suppressor that inhibits 
gastric cancer metastasis, but is also involved in 
neurological development and functions. In particular, the 
expression level of miR-148a is lower in patients with 
Parkinson’s disease compared to that in normal controls. 
Microarray and RNA-sequence techniques enable 
monitoring expression changes of thousands of genes 
simultaneously. For both gastric cancer and Parkinson’s 
disease, numerous microarray and RNA-Sequence 
experiments such as [22–32] have been conducted to 
distinguish between the diseased patients and normal 
controls, or predict the progression of the two diseases, 
with the aid of a variety of bioinformatics tools and 
statistical methods. To the best of our knowledge, no 
investigation has been carried out to explore the link 
between gastric cancer and Parkinson’s disease, using 
the gene expression profiles generated through either 
microarray or RNA-Sequencing. The objective of this 
study is to bridge this gap by using gene expression 
profiles and the barcode algorithm [33] to investigate 




Differentially expressed genes 
 
For gastric cancer, 2,114 differentially expressed genes 
(DEGs) between the patients and the normal controls 
were identified. Among them, 1,296 exhibited a higher 
expressed proportion, and 818 had a higher silenced 
proportion higher in the gastric cancer patients 
compared to the normal controls. For Parkinson’s 
disease, 36 DEGs were identified. Of them, 33 genes 
had the propensity of being expressed higher in the 
disease group than that in the control group. Between 
the two sets of DEGs, 15 genes overlapped on each 
other (Fisher’s exact test: p=0.033). The gene symbols 
for the 15 overlapping genes are presented in Figure 1A, 
and the odds ratios (ORs) and false discovery rates 
(FDR) stratified by the gastric cancer cohort and the 
Parkinson’s disease cohort are listed in Table 1. Of 
note, in gastric cancer, several overlapped genes had 
extreme ORs (either 0 or infinite), while in Parkinson’s 
disease the ORs were basically moderate. 
 
All genes except GPX3, ZBTB16, and KCNQ1 have OR 
of >1 for gastric cancer, whereas all genes have OR of 
>1 for Parkinson’s disease, suggesting that for a patient 
who has either Parkinson’s disease or gastric cancer, 
the status of 12 genes is highly likely to be un-silenced. 
This might imply that when a person suffers from one 
disease, the likelihood of having the other disease tends 
to increase, which is consistent with the results of a 
previous epidemiology study conducted in Taiwan [14] 
and the high concurrent rate between these two 
diseases indicated by the COHD database [15]. 
Nevertheless, Lin’s study [14] indicated that race might 
play an interactive role on the association between 
Parkinson’s disease and cancers. Thus, for the Asians, 
this association tends to positive, but for the 
Caucasians, this association is more likely to be 
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negative. Since no large Western gastric cancer cohort 
or Asian Parkinson’s disease cohort on the same 
microarray platform is available on the GEO database, 
thus, whether the statement is true cannot be verified 
using the proposed procedure in this study. Further 
investigation is warranted. In contrast, the COHD 
database is based on electronic health records, which 
may introduce biases to the estimation of the 
concurrent rate of the two diseases. 
 
Lastly, a respective logistic regression model with 15 
overlapped genes as predictors was fit for either gastric 
cancer or Parkinson’s disease microarray dataset. The 
predictive capacity of resulting 15-gene signatures for 
gastric cancer and Parkinson’s disease was validated on 
external datasets. As shown by the ROC curves in 
Figure 2, the list of 15-genes was validated to perform 
fairly well; especially for gastric cancer, it achieved an 
AUC statistic of 0.93. 
 
Pathway enrichment analysis 
 
In the GO biological process category, 313 terms were 
enriched by the gastric cancer DEGs, and 10 terms were 
enriched by the Parkinson’s disease DEGs. Among 
them, three enriched biological process terms were 
commonly shared by the Parkinson’s disease DEGs and 
the gastric cancer DEGs. Fifty-one GO chemical 
component terms were indicated to be enriched by the 
gastric cancer DEGs, none was enriched by the 
Parkinson’s disease DEGs. In terms of GO molecular 
function and KEGG pathway, the numbers are 7 and 17 
for gastric cancer DEGs, 0 and 0 for Parkinson’s disease 
DEGs, respectively. Therefore, no overlapped pathways 
were found between gastric cancer and Parkinson’s 
disease regarding the GO molecular function terms, the 
GO chemical component terms, or KEGG pathways. In 
Figure 1B, the overlapped GO biological process terms 
along with their corresponding false discovery rates are 
presented. Many review articles indicated that both cell 
proliferation and differentiation as well as ubiquitin-
proteasome system play critical roles in the two diseases 
[34–37]. 
 
The three overlapped GO biological process terms 
deserve further investigation, which may facilitate 
deciphering the association between Parkinson’s disease 
and gastric cancer at the gene set level, where the 
involved genes work in coordination to influence a 




Figure 1. Venn-diagrams for differentially expressed genes identified by gastric cancer cohort and Parkinson’s disease 
cohort. (A) On the gene level. (B) On the level of enriched Gene Ontology annotation. PD, Parkinson’s disease; GC, gastric cancer; GO, gene 
ontology; BP, biological process. The gene symbols indicated by the GeneCards database to directly associate with gastric cancer and 
Parkinson’s disease are highlighted in green. Of note, on the gene level the overlapped rate of gastric cancer and Parkinson’s disease is 
significant according to a Fisher’s exact test (p=0.033). 
www.aging-us.com 4 AGING 
Table 1. Overlapped differentially expressed genes by gastric cancer and 
Parkinson’s disease cohorts. 
 Gastric cancer Parkinson’s disease 
 OR FDR OR FDR 
CTSD 13.073 4.43×10-23 2.439 0.010 
GPX3 0 1.70×10-26 2.320 0.014 
SPINT1 4.134 3.27×10-6 2.563 0.024 
LTBR 11.191 3.40×10-14 2.416 0.006 
UBE2M 2.719 5.10×10-4 4.163 0.030 
NUP98 ∞ 0.013 2.126 0.033 
CEBPA 17.688 1.73×10-8 2.519 0.005 
KCNQ1 0.304 2.30×10-6 2.139 0.030 
GMDS 3.267 2.16×10-3 3.011 0.048 
ABHD2 ∞ 2.07×10-5 2.631 0.026 
ZBTB16 0.046 3.51×10-14 2.116 0.030 
CSNK1D 56.713 1.89×10-14 2.308 0.034 
RNF19B ∞ 3.42×10-5 2.437 0.010 
SRA1 32.759 5.97×10-9 2.437 0.013 
90-= 2.350 0.025 2.443 0.044 
OR: odds ratio, FDR: false discovery rate; ∞: infinite value resulting from have 0’s values 
in off-diagonal corresponding 2×2 tables. 
Analysis at the network level 
 
Using the String software, only four connections 
(CSNK1D to ZBTB16, ZBTB16 to RNF19B, RNF19B 
to CSNK1D, and ZBTB16 to CEBPA) were revealed for 
the 15 overlapped genes. As a result, a data-driven 
strategy was used to obtain the information on gene-to-
gene interactions (as stated in the Methods section). The 
corresponding networks for the information on co-
expression of the 15 overlapped genes between 
Parkinson’s disease and gastric cancer (through the 
calculation of Spearman’s correlation coefficients), are 
presented in Figure 3. Among the gastric cancer 




Figure 2. ROC curves showing predictive performance of the identified 15-gene signature. (A) For Parkinson’s disease. (B) For 
gastric cancer. Here, external validation sets were used. AUC, area under curve; GC, gastric cancer; PD, Parkinson’s disease. 
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isolated from each other, whereas among the controls, 
three gene pairs (SPINT1 and GMDS, GMDS and 
TNRC18, and CSNK1D and RNF19B) are connected. 
This may correspond to a loss of connectivity in the 
gastric cancer patients, which is consistent with the 
findings by Anglani et al. [38]. In contrast, for 
Parkinson’s disease patients, five pairs of connections 
were gained, six pairs were lost, while five pairs 
remained connected. Interestingly, two loss-of-
connectivity pairs for gastric cancer (SPINT1 and 
GMDS, and GMDS and TNRC18) were observed 
among the five gain-of-connectivity pairs for 
Parkinson’s disease, implying a possible opposite 
direction of change at the gene-to-gene interaction level 






The biological relevance of the 15 overlapping genes to 
gastric cancer and Parkinson’s disease was explored in 
the GeneCards database [39], and PubMed was searched 
for more recent information. The GeneCards [39] search 
revealed that nine of the 15 overlapping DEGs are 
directly associated with gastric cancer. Meanwhile, four 
genes related to Parkinson’s disease (CTSD, GPX3, 
CSNK1D, and UBE2M) are included in the nine genes 
directly related to gastric cancer. The remaining 
overlapping genes are all indirectly associated with either 
gastric cancer or Parkinson’s disease. 
 
According to the GeneCards [39], Cathespin D (CTSD) 
exhibits pepsin-like activity and plays a role in protein 
turnover and in the proteolytic activation of hormones 
and growth factors. CTSD may be involved in the 
pathogenesis of several diseases, including breast 
cancer and Alzheimer's disease. The pathways related to 
CTSD include lysosome and degradation of the 
extracellular matrix, and related GO annotations include 
aspartic-type endopeptidase activity. Liu et al. [40] 
showed through western blot assay that the CTSD 
protein is significantly up-regulated in the gastric cancer 
tissues compared to the normal tissues. Another study 
[41] showed this regulation pattern using 
immunohistochemistry. On the other hand, the CTSD 
levels in Parkinson’s disease patients show a consistent 
over-expression pattern across several studies, as 
pointed out in a recent review [42]. 
 
The pathways, with which glutathione peroxidase 3 
(GPX3) has been associated, include folate metabolism 
and detoxification of reactive oxygen species, and GO 
terms are transcription factor binding and selenium 
binding. In a recent study [43], using two microarray 
data, viz, GSE99039 (the dataset we used in this study) 
and GSE72267 as the training set, GPX3 was identified 
as a DEG for Parkinson’s disease as well. Subsequently, 
the over-expression of this gene in the diseased tissues 
was experimentally validated by qRT-PCR. In contrast, 
GPX3 expression was shown to be lower in gastric 
cancer patients compared to the normal tissues, and the 
overexpression of GPX3 can inhibit gastric cancer cell 
migration and invasion [43]. Meanwhile, another recent 
study [44] used the The Cancer Genomic Atlas data to 
show that GPX3 was hypermethylated in gastric cancer, 





Figure 3. Data-driven gene-to-gene interaction networks of the overlapped 15 genes. (A) For the control group in Parkinson’s 
disease. (B) For the diseased group in Parkinson’s disease. (C) For the control group in gastric cancer. PD, Parkinson’s disease; GC, gastric 
cancer. The edges highlighted in red are unique for the corresponding categories. Specifically, among the gastric cancer patients, all the 15 
overlapped genes are isolated from each other, whereas among the controls, 3 gene pairs (SPINT1 and GMDS, GMDS and TNRC18, and 
CSNK1D and RNF19B) are connected. In contrast, for Parkinson’s disease patients 5 pairs of connections are gained, 6 pairs are lost, while 5 
pairs remain connected. 
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The related pathways of casein kinase 1 delta 
(CSNK1D) are neuroscience and organelle biogenesis 
and maintenance. GO annotations related to this gene 
include transferase activity, transferring phosphorus-
containing groups and protein tyrosine kinase activity. 
UBE2M gene codes for Ubiquitin conjugating enzyme 
E2 M protein. Among its related pathways are signaling 
by GPCR and regulation of activated PAK-2p34 by 
proteasome mediated degradation. GO annotations 
related to this gene include ubiquitin-protein transferase 
activity and ubiquitin protein ligase activity. As far as 
these two genes are considered, there are no recent 
experiments reported in PubMed to provide more 
support on their relevance to either Parkinson’s disease 
or gastric cancer. 
 
Of note, a long non-coding RNA, steroid receptor RNA 
activator 1 (SRA1), has been experimentally validated to 
play roles in a variety of cancer types, including breast 
cancer, prostate cancer, and liver cancer. While there is 
no experimental evidence on its association with gastric 
cancer and Parkinson’s disease, it was predicted to 
associate with these two diseases using computational 
methods in the lncRNADisease2.0 database [45]. 
Therefore, exploration of the potential association 
between these two diseases in terms of lncRNAs may 




Using gene expression profiles and the barcode 
algorithm, we show that two distinct diseases, 
Parkinson’s disease, and gastric cancer are indeed 
linked to each other at the molecular level. Our future 
work will focus on two questions, whether the 
association is positive or negative and whether and how 
race or certain environmental factors influence the 
association between these two diseases. 
 
To conclude, the present study may serve as a pilot 
study, and it may inspire more research to evaluate the 
relationship between cancer and neurodegenerative 
diseases from the perspective of genes and their 
interaction networks. 
 




The barcode algorithm was used in this study to identify 
differentially expression genes between the diseased 
group and the control group. Therefore, some 
restrictions on the microarray platforms were imposed. 
Specifically, for human studies, chips that are 
applicable to the barcode algorithm include Affymetrix 
U133A (GPL96), U133 2.0 (GPL571), U133plus 2.0 
(GPL570), and human gene 1.0 ST (GPL6244) because 
a large number of chips are required to estimate the null 
mean and variance in the method. 
 
To acquire a sufficient statistical power to evaluate the 
association between these two diseases, the sample sizes 
of both gastric cancer and Parkinson’s disease cohorts 
need to be large. As a result, two microarray experiments 
in the NIH’s Gene Expression Omnibus (GEO) repository 
from the National Institute of Health were selected: 
GSE99039 [46] for Parkinson’s disease and GSE66229 
[47] for gastric cancer. In addition, GSE20146 [22] and 
GSE79973 [28] were used as external validation sets to 
evaluate the predictive performance of the resulting gene 
list. The demographical characteristics of these four 




Raw data (CEL files) of the two microarray experiments 
were downloaded from the GEO repository and pre-
processed using the fRMA algorithm [48], which can 
provide effective control on batch effects and enable pre-
processing of a single chip [48–50]. For those multiple 
probe sets matched to the identical gene, the one with the 





The barcode algorithm proposed by McCall et al. [33] 
transformed the actual expression values into binary 
barcode values, and the expressed genes are coded with 
1’s and the silenced genes are coded with 0’s. Briefly, 
for each gene, a mixture model in the algorithm is used 
to fit the silenced and expressed distribution of observed 
log2 transformed intensity values. The mixture model is 
expressed as: 
 
( ) ( ) ( )2| ~ 1 , ,ig g g g g g g gY p N p U S   −  +   
( )2~ , g N    
( )2 ~ , g IG    
 
where Yig is the log2 expression value for gene g in 
sample i, and follows a normal distribution of N (μg, τg2) 
when gene g is silenced or has a uniform distribution of 
U(μg, Sg) when it is expressed. Here, μg denotes the 
mean of silenced genes, and Sg denotes the saturation 
value (i.e., the upper limit of gene expression values). 
Then, μg and τg2 for gene g are assumed to follow 
normal and inverse gamma distributions, respectively. 
With a hierarchical model structure, and in particular 
the introduction of higher-level parameters (α, β, ξ, and 
λ), more stable estimates of variances for silenced genes
www.aging-us.com 7 AGING 
Table 2. Characteristics of microarray experiments in this study. 




[46] Yes GPL570 205 233 Western 
GSE66229 (gastric 
cancer)  




[22] Yes GPL570 10 10 Western 
GSE79973 (gastric 
cancer) 
[28] Yes GPL570 10 10 Asian 
 
are expected because the information across genes is 
borrowed and shared across genes, leading to a 
shrinkage of estimates for individual genes toward the 
overall level. 
 
To determine if a gene is silenced or expressed, the 
standardized intensity value, (yig − μg)/τg, was calculated. 
Upon a pre-determined cutoff value C, the expression 
barcode for a gene, a vector of 1’s and 0’s is defined as, 
 
( )( )1    /











where Φ is the cumulative density function of a 
standard normal, parameter estimation in this 
hierarchical model is done using a modified 
expectation-maximization algorithm (the details of the 
barcode are available in the supplementary material of a 
previous study [33]). The barcode algorithm was 
implemented by the barcode function in the R fRMA 
package, and the default value of C was used. 
 
Differentially expressed genes 
 
On the barcode values, the genes with all values of either 
1’s or 0’s for the respective gastric cancer and Parkinson’s 
disease cohorts were eliminated, and finally, 8,392 probe-
sets were fed into the downstream analysis. 
 
To determine if the expressed ratios differed in the 
diseased group versus the control group, Fisher’s exact 
test for individual genes was carried out upon the 
barcode values. Genes with a false discovery rate (FDR) 
of < 0.05, which was calculated through the Benjamini-
Hochberg (BH) procedure [51] to adjust for multiple 
testing issue, were considered as differentially 
expressed genes in the respective gastric cancer and 
Parkinson’s disease cohorts. The flowchart of the 




Figure 4. Flowchart illustrating how the differentially expressed genes are identified with the aid of barcode algorithm. 
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Pathway enrichment analysis and network 
construction 
 
Using the R clusterProfilter package, the Kyoto 
Encyclopedia of Genes and Genomes (KEGG) pathway 
enrichment analysis and Gene Ontology (GO) 
functional annotation were carried out on the 
differentially expressed genes of the gastric cancer 
cohort and the Parkinson’s disease cohort, respectively. 
In these analyses, all default parameters were used, and 
minimum gene set size parameter was set at 5 in the 
enrichGO function and the enrichKEGG function. 
 
Information on data-driven gene-to-gene interaction 
information was obtained by calculating Spearman’s 
correlation coefficients among the overlapped 
differentially expressed genes. If the absolute value of 
Spearman’s correlation coefficients is >0.4 and the 
corresponding false discovery rate is < 0.05, the specific 
gene pair is connected. Otherwise, they are not 
connected. The resulting data-driven gene-to-gene 
interaction information was used to plot network graph 




The GeneCards database [39] was mined to investigate 
the biological relevance of identified differentially 
expressed genes for gastric cancer and Parkinson’s 
disease. In addition, PubMed was searched for more 
recent literature on the potential relationship between 
the overlapped differentially expressed genes with 




All statistical analyses were carried out in R 3.3 
(https://www.r-project.org/). 
 
Availability of data and materials 
 
Four microarray datasets were downloaded from the 




Conceived and designed the study: ST CW. Data 
analysis: SZ MT ST. Result interpretation: SZ MT CW 
ST. Wrote the paper: ST CW. All authors reviewed and 




The University of Kentucky Markey Cancer Center’s 
Research Communications Office assisted with 
preparation of this manuscript. 
CONFLICTS OF INTEREST 
 





This study was supported by No. JJKH20190032KJ 
from the Education Department of Jilin Province and 
No. 20200201258JC of Science and Technology 




1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, 
Jemal A. Global cancer statistics 2018: GLOBOCAN 
estimates of incidence and mortality worldwide for 36 
cancers in 185 countries. CA Cancer J Clin. 2018; 
68:394–424. 
 https://doi.org/10.3322/caac.21492 PMID:30207593 
2. Obeso JA, Stamelou M, Goetz CG, Poewe W, Lang AE, 
Weintraub D, Burn D, Halliday GM, Bezard E, 
Przedborski S, Lehericy S, Brooks DJ, Rothwell JC, et al. 
Past, present, and future of Parkinson’s disease: a 
special essay on the 200th anniversary of the shaking 
palsy. Mov Disord. 2017; 32:1264–310. 
 https://doi.org/10.1002/mds.27115 PMID:28887905 
3. Chalazonitis A, Rao M. Enteric nervous system 
manifestations of neurodegenerative disease. Brain 
Res. 2018; 1693:207–13. 
 https://doi.org/10.1016/j.brainres.2018.01.011 
PMID:29360466 
4. Bercik P, Collins SM, Verdu EF. Microbes and the 




5. Malek N, Lawton MA, Grosset KA, Bajaj N, Barker RA, 
Burn DJ, Foltynie T, Hardy J, Morris HR, Williams NM, 
Ben-Shlomo Y, Wood NW, Grosset DG, and PRoBaND 
Clinical Consortium. Autonomic dysfunction in early 
Parkinson’s disease: results from the United Kingdom 
tracking Parkinson’s study. Mov Disord Clin Pract. 
2016; 4:509–16. 
 https://doi.org/10.1002/mdc3.12454 PMID:30363477 
6. Sampson TR, Debelius JW, Thron T, Janssen S, Shastri 
GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru 
V, Chesselet MF, Keshavarzian A, Shannon KM, et al. 
Gut microbiota regulate motor deficits and 
neuroinflammation in a model of Parkinson’s disease. 
Cell. 2016; 167:1469–80.e12. 
 https://doi.org/10.1016/j.cell.2016.11.018 
PMID:27912057 
www.aging-us.com 9 AGING 
7. Meng C, Bai C, Brown TD, Hood LE, Tian Q. Human gut 
microbiota and gastrointestinal cancer. Genomics 
Proteomics Bioinformatics. 2018; 16:33–49. 
 https://doi.org/10.1016/j.gpb.2017.06.002 
PMID:29474889 
8. Driver JA. Inverse association between cancer and 
neurodegenerative disease: review of the 




9. Driver JA. Understanding the link between cancer and 
neurodegeneration. Journal of Geriatric Oncology. 
2011; 3:58–67. 
 https://doi.org/10.1016/j.jgo.2011.11.007 
10. Wirdefeldt K, Weibull CE, Chen H, Kamel F, Lundholm 
C, Fang F, Ye W. Parkinson’s disease and cancer: a 
register-based family study. Am J Epidemiol. 2014; 
179:85–94. 
 https://doi.org/10.1093/aje/kwt232 PMID:24142916 
11. Bajaj A, Driver JA, Schernhammer ES. Parkinson’s 
disease and cancer risk: a systematic review and meta-
analysis. Cancer Causes Control. 2010; 21:697–707. 
 https://doi.org/10.1007/s10552-009-9497-6 
PMID:20054708 
12. Lo RY, Tanner CM, Van Den Eeden SK, Albers KB, 
Leimpeter AD, Nelson LM. Comorbid cancer in 
Parkinson’s disease. Mov Disord. 2010; 25:1809–17. 
 https://doi.org/10.1002/mds.23246 PMID:20669266 
13. Elbaz A, Peterson BJ, Bower JH, Yang P, Maraganore 
DM, McDonnell SK, Ahlskog JE, Rocca WA. Risk of 
cancer after the diagnosis of Parkinson’s disease: a 
historical cohort study. Mov Disord. 2005; 20:719–25. 
 https://doi.org/10.1002/mds.20401 PMID:15704188 
14. Lin PY, Chang SN, Hsiao TH, Huang BT, Lin CH, Yang PC. 
Association between Parkinson disease and risk of 
cancer in Taiwan. JAMA Oncol. 2015; 1:633–40. 
 https://doi.org/10.1001/jamaoncol.2015.1752 
PMID:26181771 
15. Ta CN, Dumontier M, Hripcsak G, Tatonetti NP, Weng 
C. Columbia open health data, clinical concept 
prevalence and co-occurrence from electronic health 
records. Sci Data. 2018; 5:180273. 
 https://doi.org/10.1038/sdata.2018.273 
PMID:30480666 
16. Saito Y, Saito H. MicroRNAs in cancers and 
neurodegenerative disorders. Front Genet. 2012; 3:194. 
 https://doi.org/10.3389/fgene.2012.00194 
PMID:23056009 
17. Aramillo Irizar P, Schäuble S, Esser D, Groth M, Frahm 
C, Priebe S, Baumgart M, Hartmann N, Marthandan S, 
Menzel U, Müller J, Schmidt S, Ast V, et al. 
Transcriptomic alterations during ageing reflect the 
shift from cancer to degenerative diseases in the 
elderly. Nat Commun. 2018; 9:327. 
 https://doi.org/10.1038/s41467-017-02395-2 
PMID:29382830 
18. Buchanan JL, Taylor EB. Mitochondrial pyruvate carrier 
function in health and disease across the lifespan. 
Biomolecules. 2020; 10:1162. 
 https://doi.org/10.3390/biom10081162 
PMID:32784379 
19. Klus P, Cirillo D, Botta Orfila T, Gaetano Tartaglia G. 
Neurodegeneration and cancer: where the disorder 
prevails. Sci Rep. 2015; 5:15390. 
 https://doi.org/10.1038/srep15390 PMID:26493371 
20. Hu CW, Tseng CW, Chien CW, Huang HC, Ku WC, Lee 
SJ, Chen YJ, Juan HF. Quantitative proteomics reveals 
diverse roles of miR-148a from gastric cancer 
progression to neurological development. J Proteome 
Res. 2013; 12:3993–4004. 
 https://doi.org/10.1021/pr400302w PMID:23869555 
21. Jo JH, Park SB, Park S, Lee HS, Kim C, Jung DE, Song SY. 
Novel gastric cancer stem cell-related marker LINGO2 
is associated with cancer cell phenotype and patient 
outcome. Int J Mol Sci. 2019; 20:555. 
 https://doi.org/10.3390/ijms20030555 
PMID:30696080 
22. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, 
Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser 
MA, Grünblatt E, Moran LB, Mandel SA, et al, and 
Global PD Gene Expression (GPEX) Consortium. PGC-
1α, a potential therapeutic target for early 




23. Moran LB, Duke DC, Deprez M, Dexter DT, Pearce RK, 
Graeber MB. Whole genome expression profiling of 
the medial and lateral substantia nigra in Parkinson’s 
disease. Neurogenetics. 2006; 7:1–11. 
 https://doi.org/10.1007/s10048-005-0020-2 
PMID:16344956 
24. Zhang Y, James M, Middleton FA, Davis RL. 
Transcriptional analysis of multiple brain regions in 
Parkinson’s disease supports the involvement of 
specific protein processing, energy metabolism, and 
signaling pathways, and suggests novel disease 
mechanisms. Am J Med Genet B Neuropsychiatr 
Genet. 2005; 137:5–16. 
 https://doi.org/10.1002/ajmg.b.30195 PMID:15965975 
25. Kim SY, Kim JH, Lee HS, Noh SM, Song KS, Cho JS, Jeong 
HY, Kim WH, Yeom YI, Kim NS, Kim S, Yoo HS, Kim YS. 
www.aging-us.com 10 AGING 
Meta- and gene set analysis of stomach cancer gene 
expression data. Mol Cells. 2007; 24:200–09. 
 PMID:17978572 
26. D’Errico M, de Rinaldis E, Blasi MF, Viti V, Falchetti M, 
Calcagnile A, Sera F, Saieva C, Ottini L, Palli D, Palombo 
F, Giuliani A, Dogliotti E. Genome-wide expression 
profile of sporadic gastric cancers with microsatellite 
instability. Eur J Cancer. 2009; 45:461–69. 
 https://doi.org/10.1016/j.ejca.2008.10.032 
PMID:19081245 
27. Wang Q, Wen YG, Li DP, Xia J, Zhou CZ, Yan DW, Tang 
HM, Peng ZH. Upregulated INHBA expression is 
associated with poor survival in gastric cancer. Med 
Oncol. 2012; 29:77–83. 
 https://doi.org/10.1007/s12032-010-9766-y 
PMID:21132402 
28. He J, Jin Y, Chen Y, Yao HB, Xia YJ, Ma YY, Wang W, 
Shao QS. Downregulation of ALDOB is associated with 
poor prognosis of patients with gastric cancer. Onco 
Targets Ther. 2016; 9:6099–109. 
 https://doi.org/10.2147/OTT.S110203  
PMID:27785057 
29. Peng R, Chen Y, Wei L, Li G, Feng D, Liu S, Jiang R, 
Zheng S, Chen Y. Resistance to FGFR1-targeted therapy 
leads to autophagy via TAK1/AMPK activation in gastric 
cancer. Gastric Cancer. 2020; 23:988–1002. 
 https://doi.org/10.1007/s10120-020-01088-y 
PMID:32617693 
30. Zhang M, Hu S, Min M, Ni Y, Lu Z, Sun X, Wu J, Liu B, 
Ying X, Liu Y. Dissecting transcriptional heterogeneity in 
primary gastric adenocarcinoma by single cell RNA 
sequencing. Gut. 2020. [Epub ahead of print]. 
 https://doi.org/10.1136/gutjnl-2019-320368 
PMID:32532891 
31. Lei K, Shen Y, He Y, Zhang L, Zhang J, Tong W, Xu Y, Jin 
L. Baicalin represses C/EBP β via its antioxidative effect 




32. Jia E, Pan M, Liu Z, Zhou Y, Zhao X, Dong J, Bai Y, Ge Q. 
Transcriptomic profiling of differentially expressed genes 
and related pathways in different brain regions in 
Parkinson's disease. Neurosci Lett. 2020; 732:135074. 
 https://doi.org/10.1016/j.neulet.2020.135074 
PMID:32446776 
33. McCall MN, Uppal K, Jaffee HA, Zilliox MJ, Irizarry RA. 
The gene expression barcode: leveraging public data 
repositories to begin cataloging the human and murine 
transcriptomes. Nucleic Acids Res. 2011; 39:D1011–15. 
 https://doi.org/10.1093/nar/gkq1259 PMID:21177656 
34. Li N, Lu N, Xie C. The hippo and Wnt signalling 
pathways: crosstalk during neoplastic progression in 
gastrointestinal tissue. FEBS J. 2019; 286:3745–56. 
 https://doi.org/10.1111/febs.15017 PMID:31342636 
35. Zhong JL, Huang CZ. Ubiquitin proteasome system 
research in gastrointestinal cancer. World J 
Gastrointest Oncol. 2016; 8:198–206. 
 https://doi.org/10.4251/wjgo.v8.i2.198 
PMID:26909134 
36. Momtaz S, Memariani Z, El-Senduny FF, Sanadgol N, 
Golab F, Katebi M, Abdolghaffari AH, Farzaei MH, 
Abdollahi M. Targeting ubiquitin-proteasome pathway 
by natural products: novel therapeutic strategy for 
treatment of neurodegenerative diseases. Front 
Physiol. 2020; 11:361. 
 https://doi.org/10.3389/fphys.2020.00361 
PMID:32411012 
37. Arrazola Sastre A, Luque Montoro M, Gálvez-Martín P, 
Lacerda HM, Lucia AM, Llavero F, Zugaza JL. Small 
GTPases of the Ras and Rho families switch on/off 
signaling pathways in neurodegenerative diseases. Int J 
Mol Sci. 2020; 21:6312. 
 https://doi.org/10.3390/ijms21176312 
PMID:32878220 
38. Anglani R, Creanza TM, Liuzzi VC, Piepoli A, Panza A, 
Andriulli A, Ancona N. Loss of connectivity in cancer co-
expression networks. PLoS One. 2014; 9:e87075. 
 https://doi.org/10.1371/journal.pone.0087075 
PMID:24489837 
39. Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, 
Shmoish M, Nativ N, Bahir I, Doniger T, Krug H, Sirota-
Madi A, Olender T, Golan Y, et al. GeneCards version 3: 




40. Liu F, Zhang Y, Men T, Jiang X, Yang C, Li H, Wei X, 
Yan D, Feng G, Yang J, Bergquist J, Wang B, Jiang W, 
et al. Quantitative proteomic analysis of gastric 
cancer tissue reveals novel proteins in platelet-
derived growth factor b signaling pathway. 
Oncotarget. 2017; 8:22059–75. 
 https://doi.org/10.18632/oncotarget.15908 
PMID:28423550 
41. Zhang J, Jin Y, Xu S, Zheng J, Zhang QI, Wang Y, Chen J, 
Huang Y, He X, Zhao Z. AGR2 is associated with gastric 
cancer progression and poor survival. Oncol Lett. 2016; 
11:2075–83. 
 https://doi.org/10.3892/ol.2016.4160 PMID:26998125 
42. Xicoy H, Peñuelas N, Vila M, Laguna A. Autophagic- and 
lysosomal-related biomarkers for Parkinson’s disease: 
lights and shadows. Cells. 2019; 8:1317. 
www.aging-us.com 11 AGING 
 https://doi.org/10.3390/cells8111317  
PMID:31731485 
43. Cai M, Sikong Y, Wang Q, Zhu S, Pang F, Cui X. Gpx3 
prevents migration and invasion in gastric cancer by 
targeting NFкB/Wnt5a/JNK signaling. Int J Clin Exp 
Pathol. 2019; 12:1194–203. 
 PMID:31933934 
44. Zhou C, Pan R, Li B, Huang T, Zhao J, Ying J, Duan S. 
GPX3 hypermethylation in gastric cancer and its 
prognostic value in patients aged over 60. Future 
Oncol. 2019; 15:1279–89. 
 https://doi.org/10.2217/fon-2018-0674 
PMID:30924352 
45. Bao Z, Yang Z, Huang Z, Zhou Y, Cui Q, Dong D. 
LncRNADisease 2.0: an updated database of long non-
coding RNA-associated diseases. Nucleic Acids Res. 
2019; 47:D1034–37. 
 https://doi.org/10.1093/nar/gky905 PMID:30285109 
46. Shamir R, Klein C, Amar D, Vollstedt EJ, Bonin M, 
Usenovic M, Wong YC, Maver A, Poths S, Safer H, 
Corvol JC, Lesage S, Lavi O, et al. Analysis of blood-
based gene expression in idiopathic Parkinson disease. 
Neurology. 2017; 89:1676–83. 
 https://doi.org/10.1212/WNL.0000000000004516 
PMID:28916538 
47. Oh SC, Sohn BH, Cheong JH, Kim SB, Lee JE, Park KC, 
Lee SH, Park JL, Park YY, Lee HS, Jang HJ, Park ES, Kim 
SC, et al. Clinical and genomic landscape of gastric 




48. McCall MN, Bolstad BM, Irizarry RA. Frozen robust 




49. McCall MN, Irizarry RA. Thawing frozen robust multi-




50. McCall MN, Jaffee HA, Irizarry RA. fRMA ST: frozen 
robust multiarray analysis for affymetrix exon and gene 
ST arrays. Bioinformatics. 2012; 28:3153–54. 
 https://doi.org/10.1093/bioinformatics/bts588 
PMID:23044545 
51. Benjamini Y, Hochberg Y. Controlling the False 
Discovery Rate: A Practical and Powerful Approach to 
Multiple Testing. Journal of the Royal Statistical 
Society: Series B (Methodological). 1995; 57:289–300. 
 https://doi.org/10.1111/j.2517-6161.1995.tb02031.x 
52. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. 
Cytoscape 2.8: new features for data integration 
and network visualization. Bioinformatics. 2011; 
27:431–32. 
 https://doi.org/10.1093/bioinformatics/btq675 
PMID:21149340 
